Vemma’s Health Claims

September 2016: The named plaintiff and defendants (Vemma and Yibing Wang) agreed to dismiss all of the claims in this action When a complaint is dismissed with prejudice, it cannot be refiled., the reasons for which have not been disclosed.

August 2015: Plaintiffs filed an amended complaint, which no longer names Boreyko as a defendant, making similar allegations (i.e., that the company falsely markets its products as being “doctor formulated” and clinically proven to provide various health benefits when, in reality, there are no “credible studies” to support such claims).

July 2015: After the defendants – Vemma, Vemma’s CEO Benson K. Boreyko, and Vemma’s Chief Scientific Officer Yibing Wang – filed motions to dismiss, a federal judge dismissed some of the claims (including all of the claims against Boreyko) and narrowed others. To read the full decision and learn more about the dismissed and continuing claims, click here. The judge gave plaintiffs until August 14, 2015, to file an amended complaint.

October 2014: A false advertising class-action lawsuit was filed against Vemma in a New York court in October 2014 (and transferred to an Arizona court in February 2015). The complaint alleges that the company falsely markets its Vemma product line, including Vemma, Vemma Mangosteen with Essential Minerals, Vemma Renew, Vemma Next, and Vemma Verve, as liquid dietary supplements that are “doctor formulated” and clinically proven to provide various health benefits, including enhanced immunity, when, in reality, there are no reliable and competent scientific studies to support such health claims. (Horanzy et al v. Vemma Nutrition Company, Benson K. Boreyko, and Yibing Wang, Case No. 15-cv-298, D. AZ.).

To learn more about TINA.org’s continuing coverage of Vemma, click here.